USMJ 420 Outlook Includes CBD And Adult Use Marijuana Sales Growth
North American Cannabis Holdings (OTC Pink: USMJ) is optimistic about its sales growth in CBD and adult-use marijuana as the annual 420 anniversary approaches. CEO Steven Rash highlights the potential for a market revival coinciding with this event. USMJ has confirmed eligibility for a new adult-use marijuana cultivation license in New York and has a subsidiary that has been growing hemp for CBD for four years. The company has relaunched its EVERx CBD Sports Nutrition Beverage and continues to develop cannabis consumer products for future spin-offs.
- USMJ is eligible to apply for new adult-use marijuana cultivation licenses in New York.
- The company recently relaunched the EVERx CBD Sports Nutrition Beverage.
- USMJ is positioned as the central cannabis sector company within ACI Conglomerated.
- Risks and uncertainties are associated with expected sales and the company's liquidity position.
Dallas, Texas, March 21, 2022 (GLOBE NEWSWIRE) -- North American Cannabis Holdings, Inc. (OTC Pink: USMJ), with the annual 420 anniversary only one month away, today highlighted the company’s CBD and adult-use marijuana sales growth outlook.
“USMJ is ready to hit its stride this 420 [April 20, 2022] following the reorganization of PURA and PJET with USMJ becoming the cannabis sector focus,” said USMJ CEO Steven Rash. “We are excited for the annual upcoming 420 anniversary and optimistic this 420 will coincide with an overall bullish market revival.”
USMJ, Puration, Inc. (OTC Pink: PURA) and Priority Aviation, Inc. (OTC Pink: PJET) are all controlled by ACI Conglomerated. ACI, last year reorganized its operations across the three companies with USMJ becoming the central cannabis sector company.
USMJ recently relaunched the EVERx CBD Sports Nutrition Beverage at the annual Arnold Sports Festival and now has plans to move into the adult-use marijuana market.
New York recently passed a new law to provide provisional marijuana cultivation licenses to existing hemp businesses. USMJ has confirmed its eligibility to apply for the new adult-use marijuana cultivation license recently passed into law in the State of New York.
USMJ has a subsidiary that has been growing hemp for CBD for the past four years. The subsidiary last week received an invitation from the New York Office of Cannabis Management (OCM) to apply for the provisional adult-use cannabis license.
USMJ is founded on the core belief that cannabis makes people's lives better. Cannabis can fight disease, improve wellness and do so in an environmentally sustainable manner. North American Cannabis Holdings is dedicated to finding the best possible applications for cannabis to serve consumers. The Company operates USMJ.com and is dedicated to Ongoing Cannabis Consumer Product Development that it can incubate into Future Spin-offs.
USMJ has one spin-off and dividend issuance so far in its cannabis incubation operational history having issued shares of Puration, Inc. (OTC Pink: PURA) to USMJ shareholders in the past. USMJ continues to work closely with PURA and recently acquired a CBD sports nutrition beverage product from PURA in a royalty agreement. The EVERx CBD Sports Nutrition Beverage acquired by USMJ is bottled by Alkame Holdings, Inc. (OTC Pink: ALKM).
Visit the company’s ecommerce site now and bookmark the site to watch for more coming announcements and updates: www.USMJ.com
Contact:
USMJ
Steven Rash
info@aciconglomerated.com
+1 (800) 861-1350
Disclaimer/Safe Harbor: This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that Alkame will achieve significant sales, the failure to meet schedule or performance requirements of the Company's contracts, the Company's liquidity position, the Company's ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.
FAQ
What is the growth outlook for USMJ's cannabis sales?
Is USMJ eligible for adult-use marijuana licenses in New York?
What recent product has USMJ relaunched?
What is ACI Conglomerated's role with USMJ?
What risks does USMJ face according to the press release?
